IRIS
BUCCISANO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 43341
EU - Europa 3822
AS - Asia 1080
SA - Sud America 37
OC - Oceania 24
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 13
Totale 48336
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 43296
DE - Germania 1154
CN - Cina 648
UA - Ucraina 612
IE - Irlanda 570
IT - Italia 519
GB - Regno Unito 229
KR - Corea 229
FR - Francia 171
SE - Svezia 140
RU - Federazione Russa 131
FI - Finlandia 123
BE - Belgio 41
PL - Polonia 41
CA - Canada 35
NL - Olanda 28
IN - India 26
JP - Giappone 21
AU - Australia 20
IR - Iran 20
VN - Vietnam 19
UZ - Uzbekistan 17
AT - Austria 16
BR - Brasile 13
PH - Filippine 13
EG - Egitto 12
TH - Thailandia 12
CL - Cile 10
ES - Italia 10
MX - Messico 10
EU - Europa 9
HK - Hong Kong 9
PE - Perù 9
CH - Svizzera 8
MY - Malesia 8
ID - Indonesia 7
PK - Pakistan 7
PT - Portogallo 7
SA - Arabia Saudita 7
TR - Turchia 6
TW - Taiwan 6
IQ - Iraq 5
SG - Singapore 5
A2 - ???statistics.table.value.countryCode.A2??? 4
GR - Grecia 4
NO - Norvegia 4
RO - Romania 4
AR - Argentina 3
BD - Bangladesh 3
IL - Israele 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
BH - Bahrain 2
CO - Colombia 2
HU - Ungheria 2
KG - Kirghizistan 2
MA - Marocco 2
QA - Qatar 2
SD - Sudan 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
DK - Danimarca 1
FJ - Figi 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
NG - Nigeria 1
PS - Palestinian Territory 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 48336
Salva come PNG Salva come JPEG
Città #
Woodbridge 13566
Wilmington 11985
Houston 9181
Fairfield 1533
Ann Arbor 1086
Chandler 1086
Ashburn 673
Seattle 648
Jacksonville 535
Cambridge 530
Dublin 514
Dearborn 384
Medford 352
Beijing 225
Rome 193
Lawrence 164
Zhengzhou 151
San Diego 82
Menlo Park 59
Mülheim 58
Creede 50
Redwood City 45
Milan 44
Brussels 40
Nanjing 39
Shanghai 39
Hefei 34
Center 33
London 32
Norwalk 29
Kraków 27
Kunming 25
Seoul 25
University Park 24
Bologna 22
Falls Church 22
Hangzhou 21
Palo Alto 21
Toronto 19
Boardman 16
Mountain View 16
Guangzhou 15
Nürnberg 15
Santa Clara 15
Verona 15
Dong Ket 14
Nanchang 12
New York 12
Bang Bai Mai 11
Saint Petersburg 11
Chicago 10
Hackensack 10
Fuzhou 9
Lima 9
Los Angeles 9
Monte Vista 9
Detroit 8
Hebei 7
Helsinki 7
Innsbruck 7
Phoenix 7
Redmond 7
Roebling 7
San Francisco 7
Torre Del Greco 7
Birmingham 6
Hanover 6
Jinan 6
Kuala Lumpur 6
Mumbai 6
Paris 6
San Jose 6
Shenyang 6
Wuhan 6
Cairo 5
Chengdu 5
Florence 5
Hanoi 5
Jeddah 5
Taipei 5
Absecon 4
Auburn Hills 4
Bari Sardo 4
Brescia 4
Changsha 4
Clearwater 4
Duncan 4
Felgueiras 4
Ladenburg 4
Leawood 4
Philadelphia 4
San Mateo 4
Siena 4
Turin 4
Beverly 3
Boston 3
Brooklyn 3
Bucharest 3
Cleveland 3
Costa Mesa 3
Totale 44026
Salva come PNG Salva come JPEG
Nome #
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 590
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 505
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 467
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 453
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 452
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 441
An unusual endoscopic finding in a patient with melena: Multiple gastric ulcers of regular shape 440
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 431
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 430
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 429
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 428
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 427
CD7 expression in acute myeloid leukemia 427
Clinical significance of CD38 expression in chronic lymphocytic leukemia 423
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 419
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 418
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 414
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance 413
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 411
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 410
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 409
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 409
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 409
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 407
Biological features of acute myeloid leukemia in the elderly 407
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 406
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 406
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 403
Cord blood transplantation in adults with acute myeloid leukaemia. 402
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 402
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 400
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 400
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 397
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 394
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 392
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 390
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 388
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 387
AML-M0: a biological and clinical profile 386
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 383
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 381
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 378
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 371
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 370
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 369
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 368
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 368
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 368
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study 366
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 366
Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery 365
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 365
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 363
Biological pattern of AML-M0 versus AML-M1: Response 363
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 363
Blood stem cell processing 362
P-glycoprotein expression in de novo acute myeloid leukemia 362
Azacitidine for the treatment of patients with acute myeloid leukemia 362
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 360
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 358
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 356
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 355
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 354
Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors 351
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 349
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 349
Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study 348
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 348
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 347
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 346
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 346
Monitoring of minimal residual disease in acute myeloid leukemia 345
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 345
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 344
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. 344
Outcomes of allogeneic stem cell transplantation for secondary therapy-related acute myeloid leukaemia 343
Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia 342
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 342
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 341
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 341
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 340
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 340
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 336
Reversible hyporegenerative anemia during natalizumab treatment 334
Treatment of low-blast count AML using hypomethylating agents 334
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 333
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 333
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 332
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 331
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 331
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 330
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 328
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 324
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 321
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 319
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 317
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 316
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission? 315
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 314
Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia 313
Totale 37610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66818
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66818
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018604 0000 00 00 000604
2018/201910558 637651516531 605940 974817 1050116613981273
2019/202012840 105310808981156 11521411 12471109 10551076733870
2020/20217478 8408657451008 769713 951711 229219328100
2021/20221970 661938167 54194 131129 167177136575
2022/20232975 285232219296 210575 407204 332511640
Totale 48905